CD19 and diffuse large B-cell lymphoma: To test the relevance of these findings in humans, we analyzed a cohort of 63 anti-CD19 CAR T-cell-treated patients with diffuse large B-cell lymphoma (DLBCL), monitoring both CAR4:CAR8 T-cell ratio in the blood and serum concentration of IFN-γ 1 week post-transfer (around the peak of CAR T-cell expansion).